Earlier this week, the U.S. Treasury .  to prevent tax inversions, a tactic in which a U.S. company buys another that’s domiciled in an overseas country with a much lower tax rate. The idea, which has grown popular with drug and device makers, is to generate a lower tax rate and also use cash parked outside the U.S. in ways that also deflect some taxes. We spoke with Robert Willens, an independent tax advisor who tracks corporate tax maneuvers, about the implications, especially for two deals – AbbVie’s planned acquisition of Shire and Medtronic’s deal to buy Covidien.